Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, filed and ster terms for its IPO on Tuesday.
The Burlingame, CA-based company plans to raise $20 million by offering 5.0 million shares at a price range of $4. At that price, Pulse Biosciences would command a fully diluted market value of $51 million.
The Burlingame, CA-based company was formed in 2014 and plans to list on the Nasdaq. It did not disclose a proposed ticker symbol. MDB Capital Group is the sole bookrunner on the deal. No pricing date was disclosed.
